VELARU GALACTIC EXHIBIT PACK — PHARMA / CLINICAL TRIALS
Jurisdiction: California (us_ca)
Modality: Text / Chat
Program: Velaru Pharma / Clinical Trials · California (galactic_pharma_us_ca)
Product ID: pharma:us_ca:bundle:text
Vertical: pharma
Generated: 2026-08-16T20:32:20.762566Z
Authority: California CPRA ADM Pack — 21 CFR Part 11 Clinical AI Audit Pack
Deadline: CPRA automated decision-making + AB 5 spillover
Velaru verify: https://velaru-erra.onrender.com/verify

EXHIBIT A — AI INVENTORY
[]

EXHIBIT B — GOVERNANCE FRAMEWORK
{
  "framework": "Velaru Mandate Registry \u2014 Pharma / Clinical Trials",
  "exhibit_authority": "California CPRA ADM Pack \u2014 21 CFR Part 11 Clinical AI Audit Pack",
  "regulatory_frameworks": [
    "FDA 21 CFR Part 11",
    "GCP ICH E6",
    "EU AI Act Annex III",
    "CPRA",
    "AB 5",
    "CCPA ADM regulations",
    "Unruh Civil Rights Act"
  ],
  "standards_alignment": [
    "POSS-2",
    "DRP-1",
    "TCB",
    "FRE 707 pre-compliance",
    "ISO 42001"
  ],
  "human_oversight": "release clinical batch / report adverse event",
  "third_party_verification": "https://velaru-erra.onrender.com/verify (operator-independent)",
  "data_lineage": "Hash-chained Ed25519 receipts; optional RFC3161 + external anchor",
  "mirror_trap": "Sponsors using vendor AI for protocol deviation detection \u2014 sponsor owns FDA finding, vendor owns nothing. \u00b7 CPRA ADM opt-out requires proof of what automated system decided \u2014 receipt is opt-out infrastructure.",
  "chain_integrity": {
    "depth": 2,
    "invariant_holds": true
  }
}

EXHIBIT D — DATA INPUTS & VALIDATION
{
  "data_validation_method": "Cryptographic receipt per AI decision; public verify without trusting deployer, vendor, or Velaru operator",
  "bias_testing_proxy": "Asymmetry score from live chain signals",
  "model_change_control": "Policy lock registry \u2014 criteria hash frozen pre-dispute",
  "logging_retention": "90-day pre-dispute window minimum; permanent verify permalinks",
  "external_validator": "Nisaba LLC / Velaru",
  "validator_independence": "Client-side Ed25519 verify; BYOK tri-receipt optional",
  "headline_stat": "21 CFR Part 11 already requires what Velaru does \u2014 not AI safety, compliance",
  "global_leaders_addressed": [
    "FDA",
    "Pfizer",
    "IQVIA",
    "Veeva",
    "EMA",
    "CPPA",
    "CA AG",
    "Silicon Valley insurers"
  ]
}

MIRROR TRAP (regulatory insight)
Sponsors using vendor AI for protocol deviation detection — sponsor owns FDA finding, vendor owns nothing. · CPRA ADM opt-out requires proof of what automated system decided — receipt is opt-out infrastructure.

NERVE CARDS — WHY GLOBAL LEADERS CARE
[
  {
    "title": "483 observations",
    "body": "FDA inspection: show audit trail for AI-flagged deviation \u2014 altered records = criminal referral pattern.",
    "source": "vertical"
  },
  {
    "title": "ICH E6 GCP",
    "body": "AI-assisted monitoring must be in validation documentation \u2014 post-hoc PowerPoint fails.",
    "source": "vertical"
  },
  {
    "title": "Trial insurance",
    "body": "Clinical trial insurers now ask AI governance questionnaire \u2014 receipts beat questionnaires.",
    "source": "vertical"
  },
  {
    "title": "[California] Trial bar capital",
    "body": "California plaintiffs bar most aggressive on AI \u2014 independent verify changes settlement calculus.",
    "source": "jurisdiction"
  },
  {
    "title": "[California] Tech HQ effect",
    "body": "Every global platform's AI policy tested first in California courts.",
    "source": "jurisdiction"
  },
  {
    "title": "[Text / Chat] Modality hook",
    "body": "Baseline \u2014 all frameworks apply to text decisions.",
    "source": "modality"
  }
]

BOOK SUMMARY: {
  "total_insureds": 0,
  "compliant": 0,
  "grace_period": 0,
  "non_compliant": 0,
  "expired": 0,
  "not_enrolled": 0,
  "compliant_pct": 0.0
}

TAM / EXPOSURE: $200B+ pharma R&D · AI in trial design exploding
INSURANCE LINES: Product liability, Clinical trial E&O

DISCLAIMER: External validation evidence pack — not legal advice, not filed rate approval.